secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2022-11-30T23:59:59+00:00
Accession:  0001193125-22-294899
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea Biotherapeutics appoints Jeffrey M. Goldberg as President and CEO
------------------------------------------------------------------------

- Jeffrey M. Goldberg appointed President, CEO, and Class III director effective Nov 29, 2022.
- Jim Kastenmayer resigns as Interim CEO, remains General Counsel and Corporate Secretary.
- Goldberg receives $600k base salary, up to 50% cash bonus, and $35k housing allowance.
- Stock option for 1,884,838 shares granted, vesting 1/4 on first anniversary then monthly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/0001193125-22-294899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/d376158d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-294899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer